Compare iShares MSCI Hong Kong ETF (EWH) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Moderna, Inc. — how do they compare? iShares MSCI Hong Kong ETF trades at $22.09 (market cap $1.16B), while Moderna, Inc. trades at $225.16 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 67.8× iShares MSCI Hong Kong ETF's market cap, and Moderna, Inc. is trading nearer its 52-week high, iShares MSCI Hong Kong ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Hong Kong ETF for 61 Days and Moderna, Inc. for 59 Days on average.
| EWH | MRNA | |
|---|---|---|
Market Cap | $1.16B | $78.65B |
Volume | 3,176,523 | 37,373,437 |
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $203.46 |
52-Week Low | $20.66 | $22.36 |
Typical Hold Time | 61 Days | 59 Days |
Enterprise Value | — | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH, the iShares MSCI Hong Kong ETF, trades at $22.06 with a 2.22% daily gain but maintains a bearish technical outlook. The ETF tracks Hong Kong equities, which face headwinds from Federal Reserve policy and US-Iran tensions, as the Hang Seng Index has declined over 11% from yearly highs. Moving averages signal strong bearish momentum while oscillators show neutral conditions, with key support at $21.
The outlook remains cautious given Hong Kong's sensitivity to US-China relations and Fed policy. Near-term performance hinges on geopolitical developments and Chinese economic data. Risks include continued institutional selling and Hang Seng volatility, but oversold conditions may attract contrarian buyers if tensions ease.
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
